Category:

Google Unveils Custom Axion Chips in Cloud Computing Arms Race

Posted on by slightbourne@noblecapitalmarkets.com

In the cloud computing battle among tech titans like Amazon, Microsoft and Google, the latest salvo comes from the internet search giant. Google (GOOG, GOOGL) has unveiled its custom Axion chips based on Arm (ARM) designs to try to reduce costs, boost performance for AI workloads, and cut reliance on outside vendors like Nvidia (NVDA).

The move puts Google in the company of rivals who have rolled out their own in-house processors in recent years. Amazon introduced its Graviton Arm chips in 2018, while Microsoft launched Arm-based chips just last November. Even smaller player Alibaba got into the custom silicon act back in 2021.

The economics have become compelling for the hyperscalers to design their own chips instead of relying on x86 processors from Intel (INTC) and AMD (AMD). Amazon has claimed its Graviton chips can provide up to 40% better price/performance compared to standard x86 instances. Google says its Axion chip offers 30% better performance than the fastest general-purpose Arm cloud VMs and a 50% boost over comparable x86 VMs. The chips also provide around 60% more energy efficiency than x86 instances for certain workloads.

Arm’s instruction set architecture allows for more compact and efficient chip designs compared to the complex x86 architecture. While Arm chips have traditionally been used in smartphones and other mobile devices, the cloud titans are now tapping Arm to power their data center workloads. The parallel computing performance of Arm chips also gives them an edge for AI applications which can leverage massive parallelism.

For Google, the new Axion CPUs are just the latest addition to its in-house chip portfolio. The company has designed its own Tensor Processing Units (TPUs) for years, with the latest Cloud TPU v5P unveiled in December being a powerhouse for AI training and inference. It has partnered with Broadcom (AVGO) to build the TPUs, with Broadcom’s CEO Hock Tan boasting last month that Google had bought “a ton” of chips from them.

Google plans to initially use the Axion CPUs for its internal workloads like the YouTube ads business, BigTable and Spanner databases, and BigQuery analytics before making them available externally. Companies like Snap (SNAP), Datadog, Elastic and OpenX are among the initial customers interested in tapping Google’s Arm silicon.

While Google’s cloud business still lags behind Amazon Web Services and Microsoft Azure, representing just 7.5% cloud infrastructure market share in 2022 compared to 62% for the leaders, every bit of performance and cost advantage helps. Custom Arm chips could give Google Cloud a pricing edge to win over more customers in the relentless cloud wars.

For investors, the Axion chips are worth watching as part of Google’s broader strategy to compete more effectively against Amazon and Microsoft in the rapidly growing cloud computing market. While Google generates over 75% of revenue from advertising currently, cloud is growing faster and is already profitable. Any assets like custom silicon that can help Google grab more cloud market share could pay off for the company and its shareholders over time.

The chip ambitions also have implications for other players in the semiconductor space like Arm, Nvidia, AMD and Intel. As cloud heavyweights increasingly go their own way with custom designs, it potentially limits their future chip demand from traditional providers. Arm could be a bright spot as its instruction set architecture becomes more embedded in data centers. But greater in-house chip efforts cast a cloud over prospects for current data center CPU vendors.

Ocugen (OCGN) – Phase 3 IND Clearance Is Good News We’ve Been Waiting For

Posted on by cpereira@noblefcm.com


Tuesday, April 09, 2024

Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 Trial Is Expected to Start Shortly. Ocugen announced that its amended IND for the OCU400 Phase 3 clinical trial has been cleared by the FDA. This allows the clinical trial to start enrolling patients, consistent with previous guidance for an April 2024 start. The company now has 3 clinical trials in progress in its ophthalmic disease programs.

Phase 3 Could Start Immediately. The trial is designed to compare patients treated with OCU400 to untreated controls. There are two arms, one enrolling patients with the RHO mutation and a “gene agnostic” arm enrolling patients who may have any of the mutations associated with RP. Each arm will randomize patients at 2:1, with 50 in each treatment group and 25 in each control group for a total enrollment of 150 patients. Patients will be treated with a single injection of OCU400.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ Inc. (AZZ) – AZZ raises guidance. We raised our numbers two weeks ago.

Posted on by cpereira@noblefcm.com


Tuesday, April 09, 2024

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

AZZ raised its FY 2025 guidance. Management increased its estimated sales, adjusted EBITDA, and adjusted diluted EPS by 15-20%. The increase incorporates a $4.5-$5.0 million reduction in financing costs due to the repricing of AZZ’s Term Loan B. It also reflects an expected improvement in results from AZZ’s partially spun off AIS division (40% owned and treated as other income). Management expects $15-$18 million of other income in FY 2025, up from the $13 million we have assumed for FY 2024 (reporting 4/22).

AIS growth reflects increased activity in the Electrical Infrastructure business units. Increased use of data centers, electric grid improvements, and general growth in manufacturing is leading to increased sales. We view higher results as sustainable and have raised our other income estimate for the years beyond FY 2025..


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

JPMorgan CEO Jamie Dimon Warns of Higher Inflation Risk

Posted on by slightbourne@noblecapitalmarkets.com

In his latest annual letter to shareholders, JPMorgan Chase CEO Jamie Dimon struck a cautious tone about the economic outlook while renewing his criticisms of the stringent regulatory environment facing big banks.

The 67-year-old executive expressed concerns that persistently elevated inflation could prove “stickier” and force interest rates higher than currently expected. He pointed to the significant government spending programs, the Federal Reserve’s efforts to shrink its massive balance sheet, and the potential disruptions to commodity markets from the ongoing Russia-Ukraine war as risks that could keep upward pressure on prices.

Dimon stated JPMorgan is prepared for interest rates to range anywhere from 2% to 8% or even higher levels if needed to tame inflation. This highlights the bank’s caution around “unprecedented forces” impacting the economy that Dimon says warrant a prudent approach.

While the U.S. economy has proven resilient so far, Dimon seems to be bracing JPMorgan and shareholders for a bumpier road ahead marked by elevated price pressures.

The letter also contained Dimon’s latest broadside against the intensifying bank regulation stemming from the 2008 financial crisis and its aftermath. He argued relationships between banks and regulatory agencies like the Federal Reserve “have deteriorated significantly” in recent years and become “increasingly less constructive.”

A particular flashpoint is a proposed new rule that would require banks to hold greater capital buffers as protection against potential losses. Dimon contends the rule would be damaging to market-making activities, hurt the ability of Americans to access mortgages and other loans, and simply push more activity into the less-regulated shadows of the financial system.

He questioned the entire post-crisis rule-making process, arguing it has been unproductive, inefficient, and potentially unsafe by driving more leverage into opaque areas. Dimon even raised the possibility of litigation if regulators refuse to change course on the new capital rule.

The increasingly embattled tone highlights the widening schism between the traditional banking sector and their regulators in Washington over the impacts of stringent new safeguards following the global financial crisis 15 years ago.

On the succession front, JPMorgan acknowledged that one of the board’s top priorities is “enabling an orderly CEO transition” from Dimon in the “medium-term” future. The filing named executives like Jennifer Piepszak and Daniel Pinto as potential candidates to eventually take over from Dimon as CEO once he steps down. Pinto, currently serving as President and COO, is viewed as immediately capable of taking over as sole CEO if a more abrupt transition is needed.

Dimon has been at the helm of JPMorgan since 2005 after joining from the bank’s merger with Bank One. In his letter, the long-tenured CEO reflected on JPMorgan becoming an “endgame winner” among the nation’s largest banks over the past two decades through that deal and others.

The bank also provided an updated estimate that its recent acquisition of the failed First Republic Bank will add closer to $2 billion in annual earnings going forward, above its initial $500 million projection. The accretive deal highlights JPMorgan’s firepower to act as a sector consolidator during times of crisis and instability.

Dimon spent part of his letter defending JPMorgan’s decision to withdraw from the Climate Action 100+ coalition focused on emissions reductions. He stated the bank will make its own “independent decisions” on emissions policies instead of being influenced by the group. Dimon also took aim at proxy advisory firms ISS and Glass Lewis, arguing they too often recommend splitting chair/CEO roles at companies without clear evidence it improves performance or operations.

While expressing pride in JPMorgan’s status as an “endgame winner,” Dimon’s latest letter also served as a defiant rejection of headwinds facing large banks from regulators, climate groups, and other outside forces. The combative leader who helped build JPMorgan into a banking titan is clearly positioning for more battles ahead as the second quarter of 2024 unfolds.

Release – Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

Posted on by cpatches

Research News and Market Data on OCGN

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).

“The initiation of the OCU400 Phase 3 clinical trial is a significant milestone for patients with RP and a pivotal event for Ocugen as a company,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen. “OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication. Until now, there has been only one marketed product to treat one of the 100 gene mutations associated with RP. Now there is real hope for all RP patients who haven’t had a treatment option.”

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic. In each arm, participants will be randomized 2:1 to the treatment group (2.5 x 1010 vg/eye of OCU400) and untreated control group, respectively.

In the Phase 1/2 OCU400 clinical trial, a Multi-Luminance Mobility Testing (MLMT) scale was the primary functional endpoint. For the Phase 3 OCU400 clinical trial, an updated mobility course will be used—Luminance Dependent Navigation Assessment (LDNA)— that includes a wider range of light intensity (0.04-500 Lux) and Lux Levels (0-9) with a uniform correlation between Lux level and Lux intensity.

“A sensitive mobility course, LDNA, was developed by Ocugen in collaboration with FDA for the Phase 3 clinical trial to allow enrollment of patients with early to advanced stages of disease,” said Dr. Arun Upadhyay, Chief Scientific Officer at Ocugen. “We are extremely encouraged that with this Phase 3 study design more than 50% of intent to treat RHO patients would meet the responder criteria, which is demonstrating 2 or greater Lux level of improvement after one year of treatment based on Phase 1/2 study results.”

Currently there are approximately 110,000 patients in the United States with RP and 1.6 million patients globally. Of these patients, more than 10% have the RHO genetic mutation.

“We believe that the gene-agnostic clinical trial design provides an appropriate therapeutic option to include patients who have greater potential of benefiting from treatment,” said Dr. Huma Qamar, Chief Medical Officer at Ocugen. “We are looking forward to working with our selected trial sites and leading retinal surgeons to deliver this novel modifier gene therapy to potentially address unmet medical needs.”

Ocugen previously announced that OCU400 has received orphan drug and RMAT designations from the FDA. With the initiation of the Phase 3 clinical trial, OCU400 remains on track for the 2026 BLA approval target.

About OCU400
OCU400 is the Company’s gene-agnostic modifier gene therapy product based on NHR gene, NR2E3. NR2E3 regulates diverse physiological functions within the retina—such as photoreceptor development and maintenance, metabolism, phototransduction, inflammation and cell survival networks. Through its drive functionality, OCU400 resets altered/affected cellular gene-networks and establishes homeostasis—a state of balance, which has the potential to improve retinal health and function in patients with inherited retinal diseases.

About RP
RP is a group of rare, genetic disorders that involve a breakdown and loss of cells in the retina, leading to vision loss and blindness. Currently, RP is associated with mutations in more than 100 genes.

There are no approved treatment options that slow or stop the progression of multiple forms of RP. Proposed treatments for RP include gene-replacement therapy, retinal implant devices, retinal transplantation, stem cells, vitamin therapy, and other pharmacological treatments. Current gene-replacement therapies are promising but are limited to treating just a single mutation. In addition, while gene therapies may provide a new functional gene, they do not necessarily eliminate the underlying genetic defect, which may still cause stress and toxic effects leading to retina degeneration. Therefore, the development of gene-specific replacement therapy is highly challenging, especially when multiple and unknown genes are involved. Thus, novel therapeutic approaches targeting broader RP disease in a gene agnostic manner offer greater hope for patients.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com 

Janet Yellen Signals Potential Tariffs on Chinese Green Energy Exports

Posted on by slightbourne@noblecapitalmarkets.com

U.S. Treasury Secretary Janet Yellen escalated trade tensions with China over its massive subsidies for green industries like electric vehicles, solar panels and batteries. During her recent four-day visit to Beijing, Yellen bluntly warned that the Biden administration “will not accept” American industries being decimated by a flood of cheap Chinese exports – a repeat of the “China shock” that hollowed out U.S. manufacturing in the early 2000s.

At the heart of the dispute are allegations that China has massively overinvested in renewable energy supply chains, building factory capacity far exceeding domestic demand. This excess output is then exported at artificially low prices due to Beijing’s subsidies, undercutting firms in the U.S., Europe and elsewhere.

“Over a decade ago, massive Chinese government support led to below-cost Chinese steel that flooded the global market and decimated industries across the world and in the United States,” Yellen said. “I’ve made it clear that President Biden and I will not accept that reality again.”

While not threatening immediate tariffs or trade actions, the stark warning shows Washington is seriously considering punitive measures if Beijing does not rein in subsidies and overcapacity. Yellen said U.S. concerns are shared by allies like Europe and Japan fearing a glut of unfairly cheap Chinese green tech imports.

For its part, China is pushing back hard. Officials argue the U.S. is unfairly portraying its renewable energy firms as subsidized, understating their innovation. They claim restricting Chinese electric vehicle imports would violate WTO rules and deprive global markets of key climate solutions.

Escalating tensions over green tech subsidies could disrupt trade flows and supply chains for renewable energy developers, electric automakers, battery manufacturers and more across multiple continents. Some key impacts for investors:

Rising Costs: Potential tariffs on Chinese solar panels, wind turbines, EV batteries and other components could increase costs for green energy projects in the U.S. and allied countries, slowing roll-out.

Shifting Competitive Landscape: Non-Chinese exporters of renewable hardware like solar from countries like South Korea, Vietnam or India may benefit from U.S. trade actions against China, increasing overall competition.

Consumer Prices: Green tech price inflation could be passed through to consumers for products like rooftop solar systems, home batteries and EVs if tariffs increase costs.

Strategic Decoupling: If tensions escalate towards a full “decoupling”, it could accelerate efforts by the U.S., Europe and others to secure their supply chains by bringing more critical green industries in-house through domestic investments and subsidies.

Stock Impacts: Depending on how tensions unfold, stocks of firms exposed to U.S.-China green tech trade flows could face volatility and disruptions in both directions. Tariffs would likely create clear winners and losers.

For now, Yellen says new forums for discussions have been created to potentially resolve overcapacity concerns. However, her blunt warnings suggest the U.S. will not hesitate to take tougher actions to protect America’s fledgling renewable energy and electric vehicle industries from alleged unfair Chinese trade practices.

Discover Emerging Growth Consumer, Communications, Media, and Technology Companies at Noble Capital Markets’ June Virtual Equity Conference

Posted on by cpatches
Watch the Presentation Replays
View the Conference eBook

  • Emerging Growth Public Consumer, Communications, Media, Technology (and more) Company Executive Presentations
  • Q&A Sessions Moderated by Noble’s Analysts and Bankers
  • Scheduled 1×1 Meetings with Qualified Investors

Noble Capital Markets, a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving emerging growth companies, is pleased to present the Consumer, Communications, Media, and Technology Emerging Growth Virtual Equity Conference, taking place June 26th and 27th, 2024. This virtual gathering is set to be an immersive experience, bringing together a unique blend of investors, industry leaders, and experts in the consumer, communications, media, and technology sectors.

Part of Noble’s Robust 2024 Events Calendar

The Consumer, Communications, Media, and Technology Emerging Growth Virtual Equity Conference is part of Noble’s 2024 event programming, featuring a range of c-suite interviews, in-person non-deal roadshows throughout the United States, two other sector-specific virtual equity conferences, and culminating in Noble’s preeminent in-person investor conference, NobleCon20, to be held at Florida Atlantic University in Boca Raton, Florida December 3-4. Keep an eye out for the official press release on NobleCon20 coming soon.

Check out the calendar of upcoming in-person non-deal roadshows here.

Sign up to receive more information on Noble’s other virtual conferences here.

What to Expect

The Consumer, Communications, Media, and Technology Emerging Growth Virtual Equity Conference will feature 2 days of corporate presentations from up to 50 innovative public consumer, communications, media, and technology companies, showcasing their latest advancements and investment opportunities. Each presentation will be followed by a fireside-style Q&A session proctored by one of Noble’s analysts or bankers, with questions taken from the audience during the presentation. Panel presentations are planned, featuring key opinion leaders in these sectors, providing valuable insights on emerging trends. Scheduled one-on-one meetings with public company executives, coordinated by Noble’s dedicated Investor Outreach team, are also available to qualified investors.

Why Your Company Should Present

Looking to increase awareness in your company and increase liquidity? Paid participation in Noble’s investor conferences, both virtual and in-person, provides that opportunity, with a tailored experience aimed at delivering substantial value. After 40 years of serving emerging growth companies, and the investors who follow them, Noble has built an investor base eager to discover where the next success story lies.

Noble’s investor base is relevant and, in many cases, new to your company. Noble’s dedicated Investor Outreach team provides unmatched exposure to investors that can invest in your company, including small money managers, family offices, RIAs, wealth managers, self-directed investors, and institutions. Most of Noble’s investors specifically seek undervalued, overlooked, emerging investment opportunities.

The cost to present includes your corporate presentation with a Q&A session proctored by one of Noble’s analysts or bankers, a webcast recording, scheduled 1×1 meetings with qualified investors, and marketing on Channelchek.

Benefits for Investors

Hear directly from the c-suite of the next innovators in consumer, communications, media, and technology and learn about new investment opportunities. The Q&A portion of each presentation gives you the opportunity to have your questions answered during or after the proctored session. The planned panel presentations are sure to provide expert insight on growing trends in the healthcare space. And, for qualified investors, one-on-one meetings are available with company executives; scheduled by Noble’s dedicated Investor Outreach team. All from the comfort of your own desk, and at no cost.

How to Register

Limited presenting slots are available

Publicly traded companies in these sectors can submit their registration details here.

If you have any questions about presenting, please contact events@noblecapitalmarkets.com

Investor / Guest attendees can register here

Interested in becoming a sponsor of Noble’s virtual and in-person investor conferences?

Contact events@noblecapitalmarkets.com for sponsorship information.

The GEO Group (GEO) – New Debt Priced; Raising PT to $17

Posted on by cpereira@noblefcm.com


Monday, April 08, 2024

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Upsized and Pricing. The GEO Group announced a private offering of $1.275 billion of senior notes, comprised of $650 million 8.625% notes due 2029 and $650 million 10.25% notes due 2031. GEO had originally sought to raise $1.2 billion. The Company also announced a new $450 million Term Loan B bearing interest at SOFR plus 5.25%. Net proceeds are anticipated to be $1.67 billion.

6.50% Convertible Notes. The Company also announced it is exchanging $177 million principal amount of its 6.50% Exchangeable Senior Notes due 2026, representing about 77% of the outstanding principal amount. GEO will pay cash and common stock for the estimated $305 million market value of the Notes, with the cash portion expected to be $177 million. At the current stock price, the remaining $128 million of principal amount would be exchanged for approximately 9.1 million GEO shares.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Comstock Inc. (LODE) – Accelerating Commercialization Across Multiple Business Lines

Posted on by cpereira@noblefcm.com


Monday, April 08, 2024

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First quarter 2024 perception report. RB Milestone, Comstock’s investor relations firm, released its first quarter 2024 stakeholder perception report which provides insight into Comstock’s operational milestones and strengths and weaknesses as perceived by stakeholders. The accompanying presentation highlighted the achievement of significant company milestones, notably in its Metals and Fuels segments. An underreported point made during the presentation is that Comstock has approximately $225 million of net operating loss tax carry-forward that may be used to offset gains from sales of non-core assets and future profits.

Growing customer commitments. During the first quarter, Comstock Metals received all permits for its solar panel recycling facility and began commissioning the plant. Comstock Metals has received over 60 tons of end-of-life solar panels for which it has received cash and expects to begin recognizing revenue in the second quarter as the panels are processed. Supplier commitments have exceeded expectations and Comstock is preparing permits for its first industry-scale facility.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bitcoin Depot (BTM) – Expansion Ahead of Schedule

Posted on by cpereira@noblefcm.com


Monday, April 08, 2024

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

International expansion. The company recently announced its plans to ship 125 kiosks to Australia’s largest cities, Sydney, Melbourne and Brisbane, in Q2 2024. Notably, we believe there is a sizeable opportunity for growth in Australia, which has a population of approximately 27 million people, and less than 1000 Bitcoin ATM’s in the entire county. In addition to Australia, the company expanded to Puerto Rico in March, adding 87 kiosks.

Franchise opportunities. In our view, the company should benefit from franchising, which offers the company a capital efficient method to expand operations. Notably, the company captures roughly 30%-50% of profits from franchise locations with virtually no capital committed. We view the relatively new franchise program favorably.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Maia Biotechnology To Present At Two Investor Conferences In April 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MAIA

April 05, 2024 8:01am EDTDownload as PDF

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at two investor conferences during the month of April: the 14th Annual LD Micro Invitational taking place April 8-9, 2024, in New York City; and the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference taking place April 17-18, 2024.

LD Micro:

Presentation:04:30PM ET on April 09, 2024*
Format:In-person and virtual
Location:Sofitel New York, New York City
Conference registration:Visit the conference website
Livestream registration:Visit Sequire Events
1×1 meetings:Upon request by registered investors

Noble Capital Markets:

Presentation:11:00AM ET on April 17, 2024*
Format:Virtual
Conference registration:Visit the conference website
1×1 meetings:Upon request by registered investors

*Please note that the presentation date and time are subject to change. Participants should refer to the final program agendas for up-to-date information.

MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO’s efficacy in non-small cell lung cancer (NSCLC) is being evaluated in THIO-101, a Phase 2 go-to-market clinical trial nearing completion, which is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment. MAIA plans to pursue the FDA’s accelerated approval program for THIO.

Recent news from MAIA’s THIO-101 trial includes:

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240405374193/en/

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released April 5, 2024

Release – Ocugen Announces Positive Data And Safety Monitoring Board Review And Initiation Of Enrollment In Medium Dose For OCU410—A Modifier Gene Therapy—In Phase 1/2 Armada Study For Geographic Atrophy

Posted on by aweinsoff@channelchek.com

Research News and Market Data on OCGN

April 5, 2024

  • Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial
  • DSMB Approval to Proceed with Medium Dose Cohort Dosing

Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.

Three subjects with geographic atrophy (GA) were dosed in the Phase 1/2 clinical trial to date. An additional three subjects will be dosed with the medium dose (Cohort 2) and three patients with the high dose (Cohort 3) of OCU410 in the dose-escalation phase.

“The DSMB has recommended moving forward to medium dose for dosing subjects with GA,” said Dr. Peter Chang, MD, FACS, DSMB Chair for the OCU410 clinical trial. “No serious adverse events (SAEs) related to OCU410 have been reported to date. I believe that this marks a critical next step towards determining the optimal dosing regimen and an important milestone for the clinical development of OCU410.”

“The positive DSMB review for the first modifier gene therapy for GA significantly builds on the favorable safety and tolerability profile exhibited by OCU410,” said Huma Qamar, M.D., MPH, Chief Medical Officer of Ocugen. “We are very enthusiastic about the potential of OCU410 as a one-time treatment for life with a single sub-retinal injection.”

Currently approved products to treat GA have significant limitations, as they require multiple injections per year and only target one pathway contributing to GA. OCU410 regulates multiple pathways involved with the disease including: lipid metabolism, inflammation, oxidative stress, and membrane attack complex (complement).

The ArMaDa clinical trial will assess the safety of unilateral subretinal administration of OCU410 in subjects with GA and will be conducted in two phases. Phase 1 is a multicenter, open-label, dose-ranging study consisting of three dose levels [low dose (2.5×1010 vg/mL), medium dose (5×1010 vg/mL), and high dose (1.5 ×1011 vg/mL)]. Phase 2 is a randomized, outcome accessor-blinded, dose-expansion study in which subjects will be randomized in a 1:1:1 ratio to either one of two OCU410 treatment groups or to an untreated control group.

Ocugen is committed to finding solutions for inherited retinal diseases as well as blindness diseases affecting millions. GA is an advanced form of dry age-related macular degeneration (dAMD) and affects approximately 1 million people in the United States.

About dAMD
dAMD affects approximately 10 million Americans and more than 266 million people worldwide. It is characterized by the thinning of the macula. The macula is the part of the retina responsible for clear vision in one’s direct line of sight. dAMD involves the slow deterioration of the retina with submacular drusen (small white or yellow dots on the retina), atrophy, loss of macular function and central vision impairment. dAMD accounts for 85-90% of the total AMD population.

About OCU410
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (ROR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role as well as inhibiting the complement system in in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
IR@ocugen.com 

Blowout U.S. Jobs Report Keeps Fed on Hawkish Path, For Now

Posted on by slightbourne@noblecapitalmarkets.com

The red-hot U.S. labor market showed no signs of cooling in March, with employers adding a whopping 303,000 new jobs last month while the unemployment rate fell to 3.8%. The much stronger-than-expected employment gains provide further evidence of the economy’s resilience even in the face of the Federal Reserve’s aggressive interest rate hikes over the past year.

The blockbuster jobs number reported by the Bureau of Labor Statistics on Friday handily exceeded economists’ consensus estimate of 214,000. It marked a sizeable acceleration from February’s solid 207,000 job additions and landed squarely above the 203,000 average over the past year.

Details within the report were equally impressive. The labor force participation rate ticked up to 62.7% as more Americans entered the workforce, while average hourly earnings rose a healthy 0.3% over the previous month. On an annualized basis, wage growth cooled slightly to 4.1% but remains elevated compared to pre-pandemic norms.

Investors closely watch employment costs for signs that stubbornly high inflation may be becoming entrenched. If wage pressures remain too hot, it could force the Fed to keep interest rates restrictive for longer as inflation proves difficult to tame.

“The March employment report definitively shows inflation remains a threat, and the Fed’s work is not done yet,” said EconomicGrizzly chief economist Jeremy Hill. “Cooler wage gains are a step in the right direction, but the central bank remains well behind the curve when it comes to getting inflation under control.”

From a markets perspective, the report prompted traders to dial back expectations for an imminent Fed rate cut. Prior to the data, traders were pricing in around a 60% chance of the first rate reduction coming as soon as June. However, those odds fell to 55% following the jobs numbers, signaling many now see cuts being pushed back to late 2024.

Fed chair Jerome Powell sounded relatively hawkish in comments earlier this week, referring to the labor market as “strong but rebalancing” and indicating more progress is needed on inflation before contemplating rate cuts. While the central bank welcomes a gradual softening of labor conditions, an outright collapse is viewed as unnecessarily painful for the economy.

If job gains stay heated but wage growth continues moderating, the Fed may feel emboldened to start cutting rates in the second half of 2024. A resilient labor market accompanied by cooler inflation pressures is the so-called “soft landing” scenario policymakers are aiming for as they attempt to tame inflation without tipping the economy into recession.

Sector details showed broad-based strength in March’s employment figures. Healthcare led the way by adding 72,000 positions, followed by 71,000 new government jobs. The construction industry saw an encouraging 39,000 hires, double its average monthly pace over the past year. Leisure & hospitality and retail also posted healthy employment increases.

The labor market’s persistent strength comes even as overall economic growth appears to be downshifting. GDP rose just 0.9% on an annualized basis in the final quarter of 2023 after expanding 2.6% in Q3, indicating deceleration amid the Fed’s rate hiking campaign.

While consumers have remained largely resilient thanks to a robust labor market, business investment has taken a hit from higher borrowing costs. This divergence could ultimately lead to payroll reductions in corporate America should profits come under further pressure.

For now, however, the U.S. labor force is flexing its muscles even as economic storm clouds gather. How long employment can defy the Fed’s rate hikes remains to be seen, but March’s outsized jobs report should keep policymakers on a hawkish path over the next few months.